Comparison of the effect of two combinations of myo-inositol and D -chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to evaluate the effect of two doses of D-chiro-inositol (DCI) in combination with Myo-inositol (MYO) in women with PCOS undergoing ICSI. This was a multicenter controlled, randomized, double-blind parallel group study with two MYO-DCI formulations for 12 weeks. The study group (SG) was administered 550 mg of MYO + 150 mg of DCI twice daily; the control group (CG) was administered 550 mg of MYO + 13.8 mg of DCI twice daily. The participants comprised 60 women with PCOS undergoing ICSI. At baseline, no differences were found between the two groups regarding age, BMI, HOMA-IR or testosterone levels. The pregnancy and live birth rates were significantly higher in the SG than in the CG (65.5 vs. 25.9 and 55.2 vs. 14.8, respectively) [risk ratio (RR) = 0.4; 95%CI (0.2, 0.79); p = .003 and RR = 0.27; 95%CI (0.10, 0.70); p = .002 respectively]. The risk of ovarian hyperstimulation syndrome (OHSS) was lower in the SG (3.44 vs. 18.5%, p = .07). The combination of MYO-DCI at high doses of DCI improves the pregnancy rates and reduces the risk of OHSS in women with PCOS undergoing ICSI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten studies specifically enrolled women with PCOS who also had infertility (25, 27, 40, 46-51, 55, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [40]
In the citing paper
“Two studies compared varying ratios of MI + DCI (40, 45).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [40]
In the citing paper
“Three studies used different combinations of MI + DCI as a comparator (40, 44, 45).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [40]
In the citing paper
“MI was provided prior to ovulation induction with letrozole for women with letrozole resistance (40), gonadotropin for ovulation induction and intrauterine insemination (46), IVF (25, 27), and IVF with ICSI (48).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [40]
In the citing paper
“One study comparing MI and metformin reported on depression and quality of life measures (40). There was no significant difference between the interventions for any of the outcomes measured.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [40]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197
Retracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting
Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, Balaban, B., Brison, D., Calderon, G., Catt, J., Conaghan, J., Cowan, L., Ebner, T., Gardner, D., Hardarson, T., et al. (2011) · Human Reproduction · doi:10.1093/humrep/der037 · Cited by 2,015
Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526 · cited 1×
“Polycystic ovary syndrome (PCOS) is a complex disease that involves reproductive and metabolic problems [1].”
BackgroundBalen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705 · cited 12×
“An RCT in women with PCOS undergoing intrauterine insemination showed that supplementation with MYO prevented OHSS [18].”
BackgroundInfluentialPotential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv025 · Cited by 334 · cited 1×
“For women with PCOS undergoing fertility treatments, reproductive improvements have been reported using drugs such as metformin or inositol in different forms, combinations or doses [2,3].”
BackgroundNaderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 255
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188 · cited 1×
“MYO supplements have been observed to improve the metabolic profile and hyperandrogenism of women with PCOS [4,5], in addition to increasing the clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET, probably improving the quality of embryos and reducing the number of unsuitable…”
BackgroundChiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182
Cited by
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“On the other hand, one study [55] considers the amount of DCI in the 40:1 ratio very low and proposes combining the two inositols using D-chiro-Ins at high doses.”
BackgroundMerviel, P., James, P., Bouée, S., Guillou, M. L., Rince, C., Nachtergaele, C., & Kerlan, V. (2021) · Reproductive Health · doi:10.1186/s12978-021-01073-3 · Cited by 120
“On the contrary, three meta-analyses failed to conclude on the effect of MI in women with PCOS [14, 21, 22].”
BackgroundResultKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“MI was provided prior to ovulation induction with letrozole for women with letrozole resistance (40), gonadotropin for ovulation induction and intrauterine insemination (46), IVF (25, 27), and IVF with ICSI (48).”
BackgroundMethodInfluentialInositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 49
“6 :1 ratio [52, 53] and Brusco studied only one at 5 :1 [54], while Januszewski looked at 10 :1 [55].”
Background
Metadata
- Authors
- Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J.
- Affiliations
- Obstetricia y Ginecologia, University of Granada, Granada, Spain;
- Biosearch Life, Granada, Spain;
- Complejo Hospitalario Torrecárdenas (ES)
- Complejo Hospitalario de Jaén (ES)
- Hospital Universitario Central de Asturias, Oviedo, Spain;
- Hospital Universitario Reina Sofía (ES)
- Clinica MARGEN, Calle Abu Said, n2 19, Granada, Spain;
- ORCID
- Maldonado, Vicente
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2019-03-16
- Volume
- 35
- Issue
- 8
- Pages
- 695-700
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2921811350
- Cited by
- 36
- References
- 37
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 6 · 2023: 5 · 2022: 1 · 2021: 11 · 2020: 5 · 2019: 2
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gynecological Endocrinology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-nd)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Centre for Industrial Technological Development (IDI-20150571)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- myo-inositol, D-chiro-inositol, polycystic ovary syndrome, intracytoplasmic sperm injection, inositol supplementation, live birth rate, pregnancy rate, ovarian hyperstimulation syndrome, insulin resistance
- MeSH terms
- Adolescent, Adult, Birth Rate, Dose-Response Relationship, Drug, Double-Blind Method, Drug Compounding, Female, Fertilization in Vitro, Humans, Infant, Newborn, Infertility, Female, Inositol, Polycystic Ovary Syndrome, Pregnancy, Ovarian Hyperstimulation Syndrome, Pregnancy Rate, Sperm Injections, Intracytoplasmic, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the effect of two combinations of myo-inositol and D -chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. https://app.cochat.ai/papers/10.1080/09513590.2019.1576620
- The paper
- Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019). Comparison of the effect of two combinations of myo-inositol and D -chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2019.1576620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.